Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy

Journal of the American Geriatrics Society

Volumn 59, Issue 9, 2011, Pages 1642-1649

  Pham, Annalise N ^a   Datta, Santanu K ^b,c   Weber, Thomas J ^b   Walter, Louise C ^d   Colón Emeric, Cathleen S ^b,e  

^a CANBERRA HOSPITAL   (Australia)

^b DUKE UNIVERSITY   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Geriatrics Research Education and Clinical Center   (United States)

Author keywords

Bisphosphonates; Cost effectiveness; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAUSE OF DEATH; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; FRACTURE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MORTALITY; OSTEOPOROSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MIDDLE AGED; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 80054769755     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03571.x     Document Type: Article

References (43)

1. Looker AC, Melton LJ, Harris TB et al. Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J Bone Miner Res 2010;25:64-71.
2. Burge R, Dawson-Hughes B, Solomon DH et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Min Res 2007;22:465-475. (Pubitemid 46797130)
3. United States. Public Health Service. Office of the Surgeon General. Bone health and osteoporosis: A report of the Surgeon General. Rockville, MD U. S. Deparment of Health and Human Services, Public Health Service, Office of the Surgeon General, 2004.
4. Haentjens P, Magaziner J, Colon-Emeric CS et al. Meta-analysis: Excess mortality after hip fracture among older women and men. Ann Intern Med 2010;152:380-390.
5. Centers for Medicare and Medicaid Services. National Health Expenditure Projections 2009-2019 [On-line]. Available at https://www.cms.gov/ NationalHealthExpendData/downloads/proj2009.pdf Accessed May 1, 2011.
6. Borgstrom F, Carlsson A, Sintonen H et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: An international perspective. Osteoporosis Int 2006;17:996-1007. (Pubitemid 43864853)
7. Kanis JA, Adams J, Borgstrom F et al. The cost-effectiveness of alendronate in the management of osteoporosis. [see comment]. Bone 2008;42:4-15.
8. Stevenson M, Jones ML, De Nigris E et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160.
9. Tosteson AN, Melton LJ II, Dawson-Hughes B et al. Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int 2008;19:437-447.
10. Schousboe JT, Taylor BC, Fink HA et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. [see comment]. JAMA 2007;298:629-637. (Pubitemid 47236414)
11. Schousboe JT, Ensrud KE, Nyman JA et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005;53:1697-1704. (Pubitemid 43109932)
12. Arias E. United States life tables, 2004. Natl Vital Stat Rep 2007;56:1-39.
13. Walter LC, Covinsky KE. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 2001;285:2750-2756. (Pubitemid 32525372)
14. Melton LJ III, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: Comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999;9:29-37. (Pubitemid 29086162)
15. Kanis JA, Borgstrom F, Johnell O et al. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporosis Int 2004;15:862-871. (Pubitemid 39506452)
16. Kanis JA, Oden A, Johnell O et al. The burden of osteoporotic fractures: A method for setting intervention thresholds. Osteoporos Int 2001;12:417-427. (Pubitemid 32606468)
17. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-521.
18. Wells G, Cranney A, Peterson J et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. [update of Cochrane Database Syst Rev 2006;(1):CD004523;PMID:17636764]. Cochrane Database of Systematic Reviews. 2008:CD004523.
19. Wells GA, Cranney A, Peterson J et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:CD001155.
20. Bianchi G, Sambrook P. Oral nitrogen-containing bisphosphonates: A systematic review of randomized clinical trials and vertebral fractures. Curr Med Res Opin 2008;24:2669-2677.
21. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-4124. (Pubitemid 32055362)
22. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082. (Pubitemid 29014065)
23. Boonen S, McClung MR, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004;52:1832-1839. (Pubitemid 41710266)
24. Curtis JR, Westfall AO, Cheng H et al. Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101, 038 new bisphosphonate users. J Bone Miner Res 2008;23:1435-1441.
25. Red Book Drug Topics, 112th Ed. Montvale, NJ: Thomson Healthcare, 2008.
26. Liu H, Michaud K, Nayak S et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166:1209-1217. (Pubitemid 43877630)
27. Databases, Tables and Calculators by Subject-CPI Inflation Calculator. Volume 2009: Bureau of Labor Statistics, US Department of Labor.
28. Physician fee schedule search. Volume 2009: Centers for Medicare and Medicaid Services, 2008.
29. Brainsky A, Glick H, Lydick E et al. The economic cost of hip fractures in community-dwelling older adults: A prospective study. J Am Geriatr Soc 1997;45:281-287. (Pubitemid 27114299)
30. Gabriel SE, Tosteson AN, Leibson CL et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002;13:323-330. (Pubitemid 34506742)
31. Leibson CL, Tosteson AN, Gabriel SE et al. Mortality, disability, and nursing home use for persons with and without hip fracture: Apopulation-based study. J Am Geriatr Soc 2002;50:1644-1650. (Pubitemid 35192535)
32. MetLife. Market Survey of Long Term Care Costs. The 2009 MetLife Market Survey of Nursing Home, Assisted Living, Adult Day Services, and Home Care Costs, October 2009 [on-line]. Available at http://www.metlife.com/assets/cao/ mmi/publications/studies/mmi-market-survey-nursing-home-assisted-living.pdf Accessed May 1, 2011.
33. De Laet CE, van Hout BA, Burger H et al. Incremental cost of medical care after hip fracture and first vertebral fracture: The Rotterdam Study. Osteoporos Int 1999;10:66-72. (Pubitemid 29428017)
34. Peasgood T, Herrmann K, Kanis JA et al. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 2009;20:853-868.
35. Kanis JA, Johnell O, Oden A et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004;15:20-26. (Pubitemid 38252435)
36. Hanmer J, Lawrence WF, Anderson JP et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 healthrelated quality-of-life scores. Med Decis Making 2006;26:391-400. (Pubitemid 44050843)
37. Gehlbach SH, Avrunin JS, Puleo E et al. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 2007;18:805-810. (Pubitemid 46684787)
38. Teng GG, Curtis JR, Saag KG. Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job? Curr Osteoporos Rep 2009;7:27-34.
39. Rojas-Fernandez CH, Lapane KL, MacKnight C et al. Undertreatment of osteoporosis in residents of nursing homes: Population-based study with use of the Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Endocr Pract 2002;8:335-342.
40. Colon-Emeric C, Lyles KW, Levine DA et al. Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int 2007;18:553-559. (Pubitemid 46354922)
41. Simonelli C, Killeen K, Mehle S et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002;77:334-338. (Pubitemid 34260741)
42. Tosteson AN, Burge RT, Marshall DA et al. Therapies for treatment of osteoporosis in US women: Cost-effectiveness and budget impact considerations. Am J Manage Care 2008;14:605-615.
43. Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022. (Pubitemid 44175011)